Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocytes; strongest in prostatic hillock cells | 0.75 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 301 | 0.91 |
| pathways Reactome | 3 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 10834
Sealed predictions
- UNC5B in oligodendrocytes, braak-0.69 (p 0.041) → -0.73 (p 0.024)held
- UNC5B in dopamine neurons, braak-0.61 (p 0.084) → -0.10 (p 0.803)receipt 10841
Swarm cases
receipt 10841: UNC5B in dopamine neurons, braak
- power
- full sample -0.37 (p 0.130, n 18), 95% CI -0.71 to +0.12. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.37 (p 0.130, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.50 (p 0.035, n 18). not the mix.
- skeptic
- leave-one-out range -0.49 to -0.29, sign flips 0; without severely affected donors -0.37 (p 0.130, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.67 (p 0.0022, n 18) vs -0.37 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for UNC5B in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up UNC5B · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.47 p 0.091 (needs p < 2.0e-4)
Receipts
loading the receipts